Topic Listing for Seattle Genetics

Accounting Firms Determinations 721 722 Shall Subject Dispute Accounting Treatment
Accounts Payable Accrued Liabilities Adc Collaboration Agreements
Adc Collaborations Adc Technology Not Been Incorporated Commercial Product Still
Adc Technology Still Early-stage Development Additional Agreements
Address Principal Executive Offices Including Zip Code Adept Collaboration Agreement Genencor International
Adjustments Changes Capitalization Change Control Dissolution Adjustments Changes Capitalization Dissolution Merger Asset Sale
Administration Administration Plan
Adopted Pursuant Agensys
Agensys Adc Co-development Agreement Agensys Co-development Agreement
Aggregate Country Territory Period Licensed Product Agreement
Ags-5 Adc Albany Molecular Research Inc
Although Reached Agreement Fda Spa Relating Brentuximab Vedotin Although Reached Agreement Fda Special Protocol Assessment Relating
Amended Restated Executive Employment Agreement Amendment
Amendment Lease Amendment Seattle Genetics 2000 Directors Stock Option Plan
Amendment Termination 2007 Plan Amendment Termination Directors Plan
Amendment Termination Plan Amendment Waivers
Amri Seattle Genetics Anniversary Date Meaning Set Forth 612
Annual Meeting Attendance Annual Meeting Stockholders Held 2006
Annual Meeting Stockholders Held 2007 Anti-cd30 Programs Sgn-30 Sgn-35
Anti-takeover Provisions Make Difficult Party Acquire Antibody-directed Enzyme Prodrug Therapy Adept
Antibody-drug Conjugates Adcs Anticipated Dedicated Equipment
Appraisal Rights Approval Seattle Genetics 2007 Equity Incentive Plan
Arizona State University Assignment
Astellas Asu Acknowledgement Shall Mean
Attachment Audit Committee
Audit Committee Report Audits
Availability Antigens Background
Background Financing Bankruptcy
Base Salary Basis Presentation
Bayer Bayer Pharmaceuticals
Beneficial Ownership Reporting Compliance Board Directors
Board Recommendation Bothell 98021
Brentuximab Vedotin Bristol-myers Squibb
Bulk Drug Substance Capital Requirements
Case Cash Equivalents
Cash-based Incentive Compensation Cd33 Patents
Celera Genomics Co-development Agreement Celera Genomics Group
Cell Lines Materials Drug Products Ceo Compensation
Certain Relationships Related Party Transactions Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certain Risks Uncertainties
Certain Rules Interpretation Agreement Schedules Certain Terms Relating
Certain Transactions Involving Related Persons Certifications
Change Mind After Returned Proxy Submitted Telephone Via Changes Disagreements Accountants Accounting Financial Disclosure
Chief Business Officer Clb-research Development
Clinical Results Development Plan Clinical Results Status
Clinical Supply Clinical Trials Fail Demonstrate Acceptable Levels Safety Efficacy
Clinical Trials Product Candidates Expensive Time Consuming Outcome Clinical Trials Product Candidates Expensive Time Consuming Take
Clinical Trials Take Longer Complete Project They Not Closing Conditions
Closing Date Co-development Agreement
Co-development Agreement Celera Genomics Group Code Ethics
Collaboration Agreement Collaboration Genentech-
Collaboration License Agreement Collaboration License Contract Manufacturing Agreements
Collaboration Products Collaboration Relationship
Collaborative Agreements Collaborators Not Able Obtain Required Regulatory Approvals Commercialize
Commercial Development Commercial Launch Means Sale Licensed Product Party Following
Commercialization Commercialization Collaboration Products
Commercialization Milestones Each Gne Shall Make Milestone Payments Commercialization Plan
Commercialization Sgn-40 Commitments
Commitments Contingencies Common Stock
Common Stock Financing Common Stock Financing Purchase Subject Stockholder Approval
Common Stock Financings Communications Board Directors
Compensation Compensation Chief Executive Officer
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Report Executive
Compensation Consultant Compensation Consultants Management Participation Decisions
Compensation Decisions Compensation Discussion Analysis
Compensation Executive Officers Compensation Philosophy Objectives
Compensatory Arrangements Certain Officers Competition
Competitors Develop Superior Products Manufacturing Capability Marketing Expertise Compliance Licensor In-licenses
Compliance Sgi In-licenses Compliance Sgi In-licenses Licensed Technology Acquisition Agreements
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Risk Condensed Balance Sheets
Condensed Consolidated Balance Sheets Condensed Consolidated Statements Operations
Condensed Quarterly Financial Data Condensed Statements Operations
Conduct Research Program Conference Call
Conference Call Details Conference Call Today 500
Conference Call Today 500 Et- Confidentiality
Conjugation Development Consent Independent Registered Public Accounting Firm
Consent Spouse Consequences Non-approval
Consequences Not Returning Proxy Abstentions Broker Non- Votes Consequences Not Returning Proxy Abstentions Broker Non-votes
Consolidated Statements Operations Contacts
Continue Need Significant Amounts Additional Capital Not Available Continuing Director Profiles
Contract Manufacturing Agreement Controls Procedures
Corporate Accomplishments Corporate Adc Collaborator Update
Corporate Collaborations Corporate Information
Counterparts Agreement Executed Each Shall Deemed Original Together Critical Accounting Policies
Curagen Current Global Credit Financial Market Conditions Negatively Impact
Currently Rely Third-party Manufacturers Other Parties Production Drug Dacetuzumab Sgn-40
Dacetuzumab Sgn-40 Product Collaboration Genentech Daiichi Sankyo
Deductibility Executive Compensation Deferral Award Benefits
Definitions Definitions Definition Improvements Set Forth Collaboration Agreement Hereby
Definitions Interpretation Definitions Rules Construction
Departure Directors Principal Officers Election Appointment Depend Small Number Collaborators Most Current Revenue Loss
Description Share-based Payment Plans Designated Antigen Means Having Genbank Accession Number
Designated Antigens Exclusive Designation Beneficiary
Development Commercialization Development Commercialization Manufacturing
Development Commercialization Unilateral Products Development Coordination
Development Program Collaboration Products Development Programs
Development Supply Agreement Development Support
Development Support Licensor Diffuse Large B-cell Lymphoma Clinical Trial
Diligence Diligence Licensee Shall Commercially Reasonable Efforts Develop Commercialize
Diligent Commercialization Direct Indemnity
Director Compensation Director Compensation Information
Director Nominee Profiles Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Directors Stock Option Plan
Dispute Resolution Dispute Resolutions Governing Law
Dividend Policy Documents Incorporated Reference
Drug Conjugation Material Means Including Not Limited Useful Drug Product Specifications
Duties Effect Expiration Termination
Election Directors Eli-lilly Icos Corporation
Eligibility Employee Benefit Plan
Employee Stock Purchase Plan Employees
Employment Agreements Employment Agreements Arrangements
Employment Contracts Enforcement Licensor Patents
Enforcement Sgi Patents Engage Future Acquisitions Increase Capital Requirements Dilute Stockholders
Engineered Monoclonal Antibodies Entry Material Definitive Agreement
Equity Compensation Plan Information Equity Incentive Plan
Estimates Exact Name Registrant Specified Charter
Except License Grants Neither Licensor Nor Affiliates Directly Except Otherwise Noted Technology Transfer Completed Within Effective
Except Per Share Amounts Exchange Act 1934
Exclusive Antigen Means Exclusive Antigen Means Collectively
Exclusive Antigen Means Collectively Replacement Exclusive License
Exclusive License Grant Exclusive License Grants
Exclusivity Executive Compensation
Executive Employment Agreement Executive Management
Executive Management Profiles Executive Officer Profiles
Executive Officers Exercise Option
Exhibits Exhibits Reports Form 8-k
Existing Licensor Technology Existing Sgi Technology
Existing Stockholders Significant Control Management Affairs Expand Antibody-drug Conjugate Collaboration
Experience Commercializing Products Own Extent Not Develop Ability Explanatory
Face Intense Competition Rapid Technological Change Result Others Face Product Liability Risks Not Able Obtain Adequate
Facet Biotech Corporation Fair Value Financial Instruments
Fair Value Inputs Fair Value Measurements
Fda Means United States Food Drug Administration Successor Federal Income Tax Consequences
Fees Milestones Royalties Fees Paid Independent Registered Public Accounting Firm
Fees Royalties Payments Fees Royalties Payments Unilateral Products
Field Means Field Means Provided Respect Shall Limited
Financial Other Information Financial Outlook
Financial Provisions Collaboration Products Financial Results
Financial Results Summary Financial Statements
Financial Statements Exhibits Financial Summary
Financing Transaction Fold Detach Here
Force Majeure Form 10-k
Form 10-k 2007 Form 10-q
Form Lock Agreement Form Opinion Counsel
Form Opinion Director Intellectual Property Form Opinion Intellectual Property Counsel
Forward-looking Statements Future Extension Options
Genencor Genencor Adept Collaboration
Genencor International Genentech
Genentech Dacetuzumab Collaboration Genentech Sgn-40 Collaboration
General General Administrative
General Administrative Expenses General Compensation Policy
General Provisions Generation Adc Technology Adept Still Early-stage Development Not
Generation Adc Technology Still Early-stage Development Generation Adc Technology Still Early-stage Development Not Yet
Generation Cd33 Products Genetically Engineered Monoclonal Antibodies
Governance Governing Law Interpretation Plan Awards
Government Regulation Grants Plan-based Awards
Guarantees Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
Highlights Pipeline Progress History Net Losses Expect Continue Incur Not Achieve
Hodgkin Lymphoma Holders Series Convertible Preferred Stock Voting Other Rights
Icos Corporation Impact Adoption Fas 123r
Impairment Long-lived Assets Imperial College London
Important Factors Affect Business Results Operations Stock Price Improvements New Technologies
Incentive Stock Option Limitations Terms Income Taxes
Increase Authorized Shares Common Stock Incur Substantial Costs Lose Important Rights Result Litigation
Indemnification Indemnification Procedures
Indemnity Independence Board Directors
Independent Registered Public Accounting Firm Fees Index
Index Exhibits Index Financial Statements
Industry Veteran David Gryska Information Audit Committee
Information Compensation Committee Information Nominating Corporate Governance Committee
Infringement Actions Brought Parties Infringement Party Rights
Initiation Clinical Trials Hodgkin Lymphoma Alcl Planned 2009- Insurance
Insurance Commencing Effective Date Each Party Shall Obtain Intellectual Property Rights
Interests Certain Persons Financing Internal Control Over Financial Reporting
Investment Income Net Investments
Investors Jcc Decisions
Jdc Decisions Laureate Pharma
Laureate Pharma Inc Legal Compliance
Legislative Actions Potential New Accounting Pronouncements Higher Insurance Letter Credit
License Agreement License Agreements
License Gne License Grants
Licensee Adc Patents Means Patent Applications Controlled Claim Licensee Inventions Meaning Set Forth 912
Licensee Know-how Means Technical Information Processes Formulae Data Licensee Meaning Set Forth Paragraph Agreement Each Reference
Licensee Meaning Set Forth Preamble Agreement Licensee Patents Means Patent Applications Claim Know-how
Licensee Shall Keep Complete Accurate Records Sufficient Detail Licenses Option Dropped Antigens
Licensor In-licenses Licensor In-licenses Means Following Agreements Between Indicated Parties
Limitation Liability Limitations
Lintuzumab Sgn-33 Liquidity Capital Resources
Lock Signatories Long-term Incentive Compensation
Lose Key Personnel Unable Attract Retain Additional Qualified Mabtech
Major Collaborators Major Customers
Major Suppliers Management Host Conference Call Today 500 Eastern Time
Manufacture Supply Manufacture Supply Collaboration Products
Manufacturing Manufacturing Supply Agreement
Marked Signed Returned Proxy Card Market Opportunities
Market Opportunity Market Prices Common Stock
Market Registrants Common Equity Related Stockholder Matters Issuer Material Supplies Technology Transfer Responsibilities
Medimmune Meetings Committees Board Directors
Millennium Millennium Takeda Oncology
Miscellaneous Monday-friday Eastern Time
Monoclonal Antibodies Cancer Therapy Monoclonal Antibody Technologies
Multiple Proxy Cards Name Registrant Specified Charter
Named Executive Officer Compensation Information Nasdaq Pharmaceutical Index Biotechnology
Nature Business Nature Business Basis Presentation
Neither Net Loss Per Share
Net Loss Per Share Attributable Common Stockholders New Plan Benefits
New Technologies Means Controlled Sgi Developed After Effective Nominating Committee
Nominating Corporate Governance Committee Nominees Board Directors
Nominees Board Directors Continuing Non-cash Accretion Preferred Stock Deemed Dividend
Non-cash Stock-based Compensation Nonrefundable Upfront License Payments Option Maintenance Fees Milestone
Nonstatutory Stock Option Agreement Nontransferability
Not Check Smaller Reporting Notice
Notice Exercise Notice Stock Option Grant
Notwithstanding Foregoing Disputes Relating Inventorship Validity Enforceability Scope Now Access Seattle Genetics Account Online
Now Access Seattle Genetics Inc Account Online Now Therefore Consideration Mutual Covenants Obligations Set Forth
Npil Pharma Number 0-32405
Operations Involve Hazardous Materials Subject Environmental Health Safety Option Exercises Stock Vested
Option Grants 2004 Option Grants 2005
Option License Agreement Option License Grant
Option Plan Directors Options
Organichem Corporation Other Agreements
Other Benefits Other Brentuximab Vedotin Product Candidates Early Stage Development
Other Business Other Collaborations
Other Events Other Information
Other Matters Other Provisions
Other Provisions Applicable Awards Other Sgn-35 Product Candidates Early Stage Development Possible
Overview Ownership Inventions
Ownership Inventions Technology Ownership Inventions Technology Data
Ownership Technology Part
Part Other Information Participation 1998 Stock Option Plan
Partnerships Proprietary Antibody Technologies Party Royalties
Party Royalties Adjustments Patent Prosecution Maintenance
Patent Prosecution Maintenance Enforcement Joint Program Improvement Patent Rights Maintenance Enforcement
Patent Rights Technology Ownership License Patents Proprietary Technology
Payment Reports Audits Payment Schedule
Payment Terms Books Records Audit Pdl Biopharma
Pipeline Pipeline Adc Collaborator Highlights
Pipeline Progress Piramal Healthcare Formerly Npil Pharma
Pivotal Trial Hodgkin Lymphoma Policies Procedures Review Related Party Transactions
Policy Deductibility Named Executive Officer Compensation Post-termination Protection
Power Attorney Ppinkstonseagencom
Pre-approval Policies Procedures Preclinical Development Support
Preliminary Sgn-40 Purified Bulk Drug Substance Specifications Prepaid Expenses Other
Price Range Common Stock Principal Accounting Fees Services
Principal Elements Compensation Pro Forma Information Periods Prior Adoption Fas 123r
Product Candidate Development Pipeline Product Candidates Early Stages Development Not Able Successfully
Product Development Pipeline Production Sgd-1006
Progenics Progress Advancing Pipeline
Properties Property Equipment
Proposal Proposals 2006 Annual Meeting
Proposals 2007 Annual Meeting Proposals 2008 Annual Meeting
Proposals 2009 Annual Meeting Proposals 2010 Annual Meeting
Proposals Voted Annual Meeting Protein Design Labs
Provides 2007 Financial Outlook Provides 2008 Financial Outlook
Provides 2009 Financial Outlook Psma Development
Public Accounting Firm Publication Voting Results
Publicity Names Purchase Price
Purpose Proxy Statement Card Purposes Plan
Qualifying Performance Criteria Quality Agreement
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Data
Quarterly Financial Data Except Per Share Queen Patents
Quorum Requirement Ratification Appointment Independent Registered Public Accounting Firm
Ratio Aggregate Territory Applied Tier Sales Shown Schedule Reasons Financing
Recent Accounting Pronouncements Recent Highlights
Recent Planned Pipeline Adc Collaborator Highlights Recitals
Reclassifications Registrants Telephone Number Including Area Code
Registrants Telephone Number Including Area Code 425 527-4000 Regulatory
Regulatory Approval Regulatory Assistance
Regulatory Matters Collaboration Products Reissues Reexaminations Confirmations Renewals Registrations Substitutions Extensions Counterparts
Rely License Agreements Certain Aspects Product Candidates Technology Rely Parties Provide Services Connection Preclinical Clinical Development
Report Independent Registered Public Accounting Firm Reports Exchange Rates
Reports Shall Due Following End Such Report Relates Representations Warranties
Representations Warranties Additional Covenants Representations Warranties Covenants
Required Vote Required Votes
Research Development Expense Research Development Expenses
Research Development Services Research Plan
Research Plan Means Program Definitively Established Preliminary Draft Research Program
Research Program Designated Antigens Research Programs
Research Support Reservation License Granted Subject Rights Reserved Clb Payments
Reservation Shares Restricted Common Stock
Restricted Investments Restrictive Covenants
Results Operations Results Operations Financial Condition
Revenue Recognition Revenues
Revision Classification Right Awards Employment
Rights Associated Shares Rights Sublicense
Rights Sublicensed Licensee Relevant Obligations Bms Agreement Shall Risks Related Business
Royalties Royalties Payable Sgi
Royalty Reductions Term Royalties Otherwise Payable Shall Rule 144 Means Including Other Subdivisions Thereof Promulgated
Sales Marketing Sales Unregistered Securities Issuer Repurchases
Sarbanes-oxley Act 2002 Schedule
Scope Work Seattle Genetics
Seattle Genetics Agensys Announce Collaboration Co-develop Commercialize Antibody-drug Seattle Genetics Announces Common Stock Offering
Seattle Genetics Announces Pricing Public Offering Common Stock Seattle Genetics Announces Proceeds Common Stock Offering
Seattle Genetics Announces Proposed Public Offering Common Stock Seattle Genetics Appoints Daniel Hoth Board Directors
Seattle Genetics Appoints Todd Simpson New Chief Financial Seattle Genetics Highlights Pipeline Progress Reports 2009 Financial
Seattle Genetics Hold Conference Call Today 430 Seattle Genetics Host Conference Call 2009 830 Eastern
Seattle Genetics Inc Seattle Genetics Receives Orphan Drug Designations Sgn-35 United
Seattle Genetics Reports 2004 Results Seattle Genetics Reports 2005 Financial Results
Seattle Genetics Reports 2005 Results Seattle Genetics Reports 2006 Financial Results
Seattle Genetics Reports 2006 Financial Results Pipeline Progress Seattle Genetics Reports 2008 Financial Results
Seattle Genetics Reports Strong Pipeline Progress 2009 Financial Seattle Genetics United States Patent Rights
Securities Exchange Securities Law Compliance Legends
Security Ownership Certain Beneficial Owners Management Security Ownership Certain Beneficial Owners Management Related Stockholder
Segments Senior Executive Annual Bonus Plan
Senior Management Senior Management Profiles
Series Convertible Preferred Stock Warrants Financing Severability
Sgi In-licenses Sgi In-licenses Means Following Agreements Between Indicated Parties
Sgi Inventions Meaning Set Forth 912 Sgi Patents
Sgi Technology Means Patents Know-how Sgn-15
Sgn-17 Sgn-19a
Sgn-30 Sgn-33
Sgn-33 Lintuzumab Sgn-35
Sgn-40 Sgn-40 Product Collaboration
Sgn-70 Sgn-70 Sgn-75
Sgn-75 Share-based Compensation
Share-based Compensation Expense Share-based Compensation Expense Fas 123r
Sigma Aldrich Fine Chemicals Signature Page Adc Collaboration Agreement
Signature Page Follows Signatures
Significant Accounting Policies Stage Lymphoma Program Brentuximab Vedotin Sgn-35
Status Stock Acceleration
Stock Awards Stock Compensation Expense
Stock Option Agreement Stock Option Plan
Stock Performance Graph Stock Price Volatile Shares Suffer Decline Value
Stock Purchase Plan Stock Purchase Warrants
Stock Subject Plan Stock-based Compensation
Stock-based Payment Award Activity Stockholder Approval Required Nasd Rules
Stockholder Approval Required Nasdaq Rules Stockholders Equity
Stockholders Sharing Same Address Strategy
Submission Matters Vote Security Holders Subsequent Event
Subsequent Events Subsequent Events Stock Purchase Subject Stockholder Approval
Summary Summary Compensation Table
Summary Plan Table Contents
Takeda Pharmaceutical Limited Tax Accounting Considerations
Technology Acquisition Agreements Technology Disclosure
Term Award Term Meaning Set Forth
Term Meaning Set Forth 131 Term Plan
Term Termination Termination
Termination Cause Termination Employment
Termination Licensee Termination Licensor In-licenses
Terms Conditions Options Terms Conditions Stock Awards
Terms Financing Shares Terms Stock Purchase Agreement
Tier Sales Meaning Set Forth Hereof Tim Carroll Cfo Since 2000 Retire
Time Place Annual Meeting Toll Free Number 1-800-370-1163
Transfer Manufacturing Technology Ucb Celltech
Unable Enforce Intellectual Property Rights Not Able Commercialize Unable Enforce Intellectual Property Rights Not Able Operate
Unfunded Plan University Miami
Valuation Assumptions Vote Mail
Vote Person Annual Meeting Vote Required
Vote Solicitation Outside Solicitors Vote Telephone Electronically Via Internet
Voting Procedure Voting Procedures
Website Whistleblower Policy
Witnesseth Year-end Option Values
~conference Call Today 500 Et~ 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki